作者: Kristina Warton , Kate L Mahon , Goli Samimi
DOI: 10.1530/ERC-15-0369
关键词:
摘要: Circulating tumor DNA (ctDNA) in the plasma or serum of cancer patients provides an opportunity for non-invasive sampling DNA. This 'liquid biopsy' allows interrogations such as quantity, chromosomal alterations, sequence mutations and epigenetic changes, can be used to guide improve treatment throughout course disease. tremendous potential real-time 'tracking' a patient has led substantial research efforts ctDNA field. distinguished from non-tumor by presence tumor-specific copy number variations, also aberrant methylation, with both methylation changes corresponding those found tumor. Aberrant specific promoter regions very consistent feature cancer, contrast mutations, which typically occur at wide range sites. consistency makes amenable design widely applicable clinical assays. In this review, we examine context monitoring disease status, response determining prognosis patients.